

Transformed Follicular Lymphoma: Not all fit in one

Vittoria Tarantino², Luana Conte¹, Martina Manni², Alessandra Dondi²,
Monica Bellei², Massimo Federico^{1,2,3}

¹Interdisciplinary Laboratory of Applied Research in Medicine (DReAM), University of Salento, Lecce, Italy

²Department of Diagnostic, Clinical and Public Health in Medicine, University of Modena and Reggio Emilia, Modena, Italy

³ Medical Oncology, Città di Lecce Hospital, GVM Care & Research, Lecce, Italy

Corresponding author: Vittoria Tarantino
vittoriatarantino@hotmail.it

Abstract

Follicular Lymphoma (FL) is the second most frequent non-Hodgkin lymphoma accounting for approximately 10-20% of all lymphomas in Western Countries. Histologic transformation (HT) is a frequent event in the clinical course of patients with indolent lymphoma that is often accompanied by a dramatic change in the clinical features of the disease towards a more aggressive course. Although the transformation of Follicular Lymphoma (tFL) was described several decades ago, there is a strong need for a better understanding of both the dynamics of the tumor clonal evolution and the genetic events leading to transformation. In addition, the management of patients with tFL is challenged by the heterogeneity of the previous treatments. The present review describes the state of art of tFL, outlining recent advances in the understanding of genetic basis and the evolutionary process governing the initiation and persistence of tumor evolution. It will be also addressed the key questions pending on this incurable disease, such as a lack of a standard therapeutic strategy for tFL patients as well as its outcome in the Rituximab (R) era.

Keywords: Non Hodgkin Lymphoma, Follicular Lymphoma, Transformed Follicular Lymphoma, immunochemotherapy

Introduction

Follicular Lymphoma is defined by the World Health Organization (WHO) classification (Swerdlow SH, Campo E 2008) as a “neoplasm composed of follicle center (germinal center – GC) B cells, typically both centrocytes and centroblasts which usually has at least a partially follicular pattern”. FL arises then by a malignant transformation of the normal germinal center B cells and therefore carries the characteristics of centrocytic/centroblastic morphology.

The disease is usually characterized by an indolent clinical course, excellent response to initial therapy with frequent relapses and shorter duration responses to salvage therapy.

At present, thanks to the advances in the treatment of FL, the disease is moving from an in-

curable to curable one. Regarding the management chemoimmunotherapy – usually followed by Rituximab maintenance – is the standard of care; whereas patients with nonbulky or asymptomatic disease may be treated with Rituximab monotherapy or simply observed (Jonathan W Friedberg et al. 2009). Although many asymptomatic patients with low-volume disease may not require early therapy and can be observed, the majority of patients will lastly experience disease progression and will need therapy during the course of the disease. In particular, some patients have long-term remission lasting years, others have a rapidly progression of the disease and develop treatment resistance and/or transformation to aggressive lymphoma (Link et al. 2013; S. M. Smith 2013). Priorities in goals of care include avoiding relapses, transformation to aggressive subtypes and death.

In the past, approximately 25% of cases transform to aggressive disease, mostly Diffuse Large B-cell Lymphoma (DLBCL), with a very poor prognosis (Montoto et al. 2007). The histologic changes seen in patients with HT are, in the great majority of cases, accompanied by a change in the clinical features of the disease towards a more aggressive course (Montoto 2015).

More recently, contradictory data are emerging with respect to the impact of initial treatment on the risk of transformation (Montoto 2015). In particular, the adoption of Rituximab in first line therapy seems associated with a lower risk of transformation. Therefore, decisions on the management of tFL patients come from extrapolation data of retrospective studies or from prospective trials in DLBCL, as this is the commonest transformed lymphoma.

The present review will be focused on the state of art of tFL and will try to address pending questions about this condition.

Definition of tFL

Definition of tFL is still a great challenge as it varies among different series. Over the past years, definition of transformation have been largely varying from “*an histological features of DLBCL as opposed to cytologic progression with an increase in the proportion of large cells (from grade 1/2 to grade 3 FL)*” (Montoto et al. 2007) to “*refractory/recurrent disease with either clinical or pathologic diagnosis of transformed lymphoma*” (Link et al. 2013); passing through other definitions. The main issue in considering a unique definition is the fact that transformation is diagnosed in different series based on cytological samples, on histologic samples or in some cases on clinical grounds alone. Indeed diagnosis should be based on biopsy or adopting clinical criteria in the cases in which it is not possible to obtain a biopsy, either because of the poor performance status of the patient or because of progression of the disease in inaccessible areas (Montoto and Fitzgibbon 2011). In 2008, Al-Tourah et al. (Al-Tourah et al. 2008) published clinical criteria to define transformation: a rapid discordant lymphadenopathy growth, unusual sites of extranodal involvements, a sudden rise in the LDH

level, hypercalcemia, or presence of new B-symptoms.

Incidence, Prognosis and Outcome of tFL

Historically, transformation was largely considered a catastrophic event. Although the clinical course of FL patients may span more than ten years, transformation occurrence heralds a change from an indolent to an aggressive disease course, and is associated with major morbidity and mortality (14). In particular, most of the studies have reported a poor prognosis after transformation, with a median duration of survival generally ranging from 2.5 months to 2 years, with most deaths being due to lymphoma (5,7,12,13,15–21).

The incidence of HT have wavered over the past several decades, due to the adoption of different diagnostic methods, definition of transformation and duration of follow-up. Thus, the considerable variability in the incidence of tFL reported in literature may be explained by the heterogeneity in the definition of transformation, population included and diagnostic tools.

The clinical significance of transformation was seen in 325 FL patients from the St Bartholomew's Hospital of London, in which the risk of transformation by 10 years was 28% and the median survival after transformation was 1.2 years. Patients with tFL had a significantly shorter OS and a shorter survival from progression compared to others (Montoto et al. 2007).

Al-Tourah et al. analyzed the incidence of HT in a population based-study of 600 patients. The annual risk of transformation was estimated to be 3% per year, and the median survival after transformation was 1.7 years (7).

In another recent study from the University of Iowa/Mayo Clinic (Link et al. 2013), the cumulative risk of transformation and death without transformation (competing risk) increased steadily over time up through 5 years of follow-up and then appeared to slow, with only four transformations observed beyond 5 years from diagnosis. Transformation rate at 5 years was highest in patients who were initially observed and lowest in patients who initially received Rituximab monotherapy (Link et al. 2013).

However, in a group of 107 patients with advanced FL and low tumor burden registered in

the F2 database and managed with a W&W policy, the 5-year risk of transformation was quite low. After a median follow-up of 64 months, five patients experienced transformation to aggressive non-Hodgkin lymphoma, two during the W&W no treatment period and three after progression, with an estimated rate of less than 1% per year (Solal-Céligny et al. 2012).

Wagner-Johnston et al. have investigated the incidence, prognostic features, and outcomes associated with tFL among 2652 patients with FL prospectively enrolled in the US National LymphoCare Study. At a median follow-up of 6.8 years, 14.3% of patients underwent transformation; patients who were treated at diagnosis had a reduced risk of transformation as well as maintenance Rituximab was associated with reduced transformation risk. The median OS post transformation was 5 years (Wagner-Johnston et al. 2015).

The clinical and laboratory findings with better Overall Survival (OS) at the time of transformation include normal LDH levels, limited disease extent, good performance status, absence of B symptoms, fewer number of previous relapses, transformation after expectant management, having had no prior CR, or having had no response to salvage chemotherapy (5,7,12,13).

Despite the overall poor outcome of tFL patients, Yuen et al., identified a subset of patients having a relatively good outcome (Yuen et al. 1995). Limited extent of disease, attainment of Complete Remission (CR) to treatment given at the time of transformation and no prior therapy had a particularly favorable prognosis. In addition, patients who achieved CR after transformation had a better OS than those with advanced stage disease (108 vs 18 months) (Yuen et al. 1995). The impact of limited disease on tFL patients' prognosis was also seen by Bastion et al., (Bastion et al. 1997) and Al-Tourah et al., (Al-Tourah et al. 2008). This latter group shown that the 5-year OS was 66% for patients with a limited transformation compared to 19% for those with advanced-stage at transformation in a significant way (Al-Tourah et al. 2008).

Only slight improvement were observed in recent studies, mostly showing the shorter OS of tFL patients in comparison to non-transformed FL patients. This adverse effect of transformation on survival was clearly illustrated by Al-

Tourah et al., where the 10-year OS for non-transformed FL patients was 75%, whereas was only 36% for tFL patients were alive 10 years from the time of their initial FL diagnosis (Al-Tourah et al. 2008). Similar behaviors were also seen in other studies (Montoto et al. 2007).

Importantly, most of the patients in the reported studies received therapies not incorporating Rituximab. However, differences in patients' series, treatment and outcome is not a good condition to take advantage of; a lot of work is still needed to find out standard clinical criteria. Table 1 summarizes transformation risk in recent series.

Table 1. Outcome of tFL patients in recent series

Studies	Transformation risk
Montoto et al., 2007	17% at 5 years (100% biopsy proven) 1.9 RR in W&W
Al-Tourah et al., 2008	18% at 5 years (63% biopsy proven) 30% at 10 years (18% Doxo vs 30% Alk P=0.001)
Link et al., 2008	10.7% at 5 years (85% biopsy proven) 14.4% in W&W 3.2% in Rituximab
Wagner et al., 2005	12.8% at 5 years (39% biopsy) 13.4% Rituximab chemotherapy 18.3% NonRituximab chemotherapy
Sarkozi et al., 2016	4.1% at 6 years (100% biopsy proven)

Can we assess any improvement in the outcome of tFL in the Rituximab era?

Whether the addition of Rituximab in initial treatment modifies the outcome of tFL patients, still needs to be addressed. However, over the last 5 years, several studies have been suggesting that the outcome of tFL patients has improve in the Rituximab era (Conconi et al. 2012; Ban-Hoefen et al. 2013; Lerch et al. 2015; Link et al. 2013; Guirguis et al. 2014).

Very recently Sarkozi and all analyzed risk factors, incidence and outcome of HT at first recurrence in the PRIMA patient cohort: after 6 years after a chemoimmunotherapy induction, the cumulative incidence of HT was 4.1% (Sarkozi et al. 2016).

Literature suggests that patients treated with Rituximab-containing chemotherapy achieve a longer OS compared with retrospective cohorts of patients treated with chemotherapy alone (Link et al. 2013; Bastion et al. 1997). In contrast, the most recent trial comparing a W&W

approach vs R did not show any differences in terms of risk of transformation (Ardeshna et al. 2014). As commented by the same authors, in the most of the reported series, the majority of patients have received chemotherapy prior to the diagnosis of HT and have advanced stage at the time of transformation so the better outcome cannot be attributed to an earlier identification of transformation leading to a better risk population (Montoto 2015).

Controversial results were also found in whether prior treatment with Rituximab has a good effect on the outcome after transformation. In a recent study, Lerch et al. (Lerch et al. 2015), showed that the treatment with Rituximab before the diagnosis of tFL was not correlated with a worse outcome in those patients. In contrast, patients with relapsed DLBCL treated with Rituximab have a significantly worse prognosis at progression (Montoto 2015). Other two studies demonstrated that prior R treatment did not result in a worse outcome in tFL patients who received high dose therapy with autologous stem cell rescue (HDT-ASCR) (Ban-Hoefen et al. 2013; Madsen et al. 2015). Patients who have previously received CHOP (Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Vincristine [Oncovin], Prednisone) chemotherapy, with or without R, are frequently treated with second line regimens for DLBCL (Montoto 2015).

The role of Rituximab maintenance in DLBCL patients is also still unconcluded. In a recent study, R Maintenance was associated with reduced transformation risk. The median OS post transformation was 5 years, suggesting an improved outcomes for transformation in the modern era (Wagner-Johnston et al. 2015). Habermann et al., (Habermann et al. 2006) showed that addition of maintenance with R did not improve the outcome of DLBCL patients treated with R-CHOP. Other two studies showed that R maintenance after HDT-ASCR in DLBCL patients was not associated with a better outcome (Haioun et al. 2009; Gisselbrecht et al. 2012).

Based on heterogeneity of the treatment used before diagnosis of HT, it is a challenge to pull out any conclusions about specific regimen.

Pathology and biology of tFL

Although the FL transformation to DLBCL was described several decades ago, there is a strong need for a better understanding of both the dynamics of tumor clonal evolution and the genetic events that are responsible for transformation.

The pathogenesis of FL is best explained by a unifying hypothesis that takes into account genetic alterations harbored by the neoplastic B cells and an immunological model that suggests prominent crosstalk between the tumor cells and non-neoplastic immune cells in the tumor microenvironment, which include T cells, macrophages, follicular dendritic cells and stromal elements (de Jong and de Boer 2009; de Jong 2005; I S Lossos 2005).

It is well known that the translocation t(14;18) characteristic of most cases of FL leads to constitutive B-cell Lymphoma 2 (BCL2) protein expression and is a critical early event in the development of FL (Izidore S. Lossos and Gascoyne 2011). These cells then slowly proliferate, but do not die by apoptosis, and they can acquire genetic alterations. This condition can include chromosomal alterations that result from the localization in the GC (Küppers 2005). Others are driver mutations and alterations that provide the malignant cells with a growth advantage including gains, losses of chromosomal material and even balanced translocations involving the activation of dominant oncogenes, such as MYC (Izidore S. Lossos and Gascoyne 2011).

Recent studies have shown divergent pathways of disease progression and transformation in FL.

Recent whole-exome studies have highlighted that low-grade FL at diagnosis frequently shows some “driver” mutations not found in the transformed clone (Okosun et al. 2014; Pasqualucci et al. 2014; Carlotti et al. 2009). Some of these data derived from genetic methods, and suggest that FL may evolve as a “non linear” transformation (Okosun et al. 2014; Pasqualucci et al. 2014; Bouska et al. 2014; Wartenberg et al. 2013; Green et al. 2013; Eide et al. 2010; Carlotti et al. 2009; Ruminy et al. 2008; Halldórsdóttir et al. 2008), in which the clone detected at transformation is more closely

related to a common progenitor than the clone predominating at the time (or site) of prior sampling (Casulo, Burack, and Friedberg 2015). The clonal evolution models to tFL were defined by investigating genomic alterations that are present in the dominant clone of both pre- and post- specimens (“Shared lesions”), and contrasting them to those that are present exclusively in the FL or tFL biopsy (“phase-specific lesions”). This analysis allowed to discriminate between i. a linear model, in which the tFL dominant clone will maintain all lesions present in the original FL clone, in combination with additional tFL-acquired alterations; ii. a divergent evolution model, where there are lesions that are unique to the dominant clone of the FL or the tFL, in addition to the set of shared alterations (Pasqualucci et al. 2014).

Thus, data mostly supported a divergent evolution model in a significant proportion of patients undergoing transformation, whereby FL and tFL arise from a common mutated ancestor through the independent acquisition of distinct lesions (Pasqualucci et al. 2014). Most FL and tFL derive from a common mutated precursor cell through divergent clonal evolution. There are some shared molecular determinants such as chromatin modification and apoptosis and some tFL specific determinants such as cell cycle, proliferation and DNA damage response.

Interestingly, the most commonly affected genes in both FL and tFL were those encoding for histone/chromatin modification enzymes, including methyltransferases and acetyltransferases (Pasqualucci et al. 2014). These early lesions in FL generally affect epigenetic regulators (genes controlling chromatin structure), including the H3H4 trimethyl-transferase *MLL2* mutation, never lost at transformation, *EZH2* and the acetyltransferases *CREBBP* and *EP300* (Okosun et al. 2014; Pasqualucci et al. 2014; Morin et al. 2010; Morin et al. 2011).

Other frequent dysregulation in both FL and tFL was represented by programmed cell death genes, in particular *BCL2* translocations, and thus presumably in the common ancestor clone (Pasqualucci et al. 2014).

Among tFL specific determinants there were alterations of cell cycle control, through mutation or deletion of cyclin-dependent kinase 2A/B (*CDKN2A/B*). These latter are two tu-

mor suppressor genes, whose protein products p14-ARF, p16-INK4A and p15-INK4B, are important for negative regulation of cell cycle G1 progression and stabilization of the tumor suppressor p53 (Pasqualucci et al. 2014; Sherr 2004).

Alterations in *Myc* (Okosun et al. 2014; Pasqualucci et al. 2014), as well as DNA damage response, through losses of genes associated with regulation of the immune response, were also consistent in tFL only. Among the mutations that affect the immune response, recent studies found the entire HLA class I locus, specifically in β -2-microglobulin (*B2M*) and *CD58* (Pasqualucci et al. 2014; Bouska et al. 2014; Morin et al. 2010).

Although a large number of prognostic markers have been implicated as contributing to survival in FL, only a handful have specifically examined the role of biological factors impacting risk of transformation.

It is becoming evident that phenotype variations related to genetics events (*MYC*, *BCL2*, p16, p53) should be routinely identified. FISH analysis could also be required to identify genetic alterations in *MYC*, *BCL2* and *BCL6*.

The incidence of *CD30* expression in tFL has also been reported to be 20% in a recent retrospective series of cases and *CD30* expression should be also routinely identified by IHC.

In summary, there is not a single mechanism driving transformation from FL to DLBCL (Okosun et al. 2014; Pasqualucci et al. 2014; Bouska et al. 2014; Andrew J. Davies et al. 2007). Rather, there are several mechanisms involved in transformation.

Treatment of tFL

Optimal treatment strategies for tFL still represents an unmet need. Unfortunately, most clinical trials exclude patients with tFL and there are no randomized studies in the modern era, with the result that level of evidence is very limited.

In historic series, as described before, the outcome of tFL patients was very poor, with a median OS of approximately 1 or 2 years (Montoto and Fitzgibbon 2011). However, the majority of published studies were conducted in the pre-Rituximab era, making difficult to draw any conclusion on the current scenario.

In the study conducted by Lynk and colleagues in 60 out of 631 patients with biopsy-proven tFL, the median OS was 50 months with an OS rate of 73% at 5 years after treatment with R-CHOP chemotherapy (Link et al. 2013). Survival was similarly in the National Comprehensive Cancer Network (NCCN) database study, with a median OS around 5 years in 118 biopsy confirmed tFL patients, was (Ban-Hoefen et al. 2013). Similar results were seen in early-stage FL experiencing tFL, with a 3-year OS of 44% (Bains et al. 2013). The estimated median OS for the patients with a histological diagnosis of HT from the PRIMA trial was 3.8 years after a median 6 year follow up (Sarkozy et al. 2016).

As response after conventional chemotherapy, high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) has been studied by several research groups (Witzig et al. 2002; Schouten et al. 1989; Freedman et al. 1991; Foran et al. 1998; Berglund et al. 2000; Chen et al. 2001; Williams et al. 2001; J W Friedberg et al. 1999; Andreadis et al. 2005; Sabloff et al. 2007; Ramadan KM, Connors JM 2008).

Of historical relevance, the efficacy of ASCT was shown in tFL patients in old phase 2 and transplant registry series prior to the incorporation of immunotherapy (Wang and Hou 2010; Montoto and Fitzgibbon 2011). In particular, 40% of patients experienced long-term benefit, with survival rates similar to patients with relapsed aggressive lymphoma receiving the same treatment (Williams et al. 2001). However, most of the transplant studies are based on only small retrospective series of 20 to 50 patients (Hamadani et al. 2008; Williams et al. 2001; Chen et al. 2001; J W Friedberg et al. 1999; Sabloff et al. 2007). The role of ASCT has been further investigated in the Rituximab era, and so more relevant to current practice with the result that the addition of the antibody has improved the outcomes of tFL patients practice.

The Canadian Bone Marrow Transplant group (CBMTG) analyzed 172 patients with tFL, 53 treated with rituximab containing chemotherapy alone and 97 underwent instead ASCT. This latter approach improved OS and Progression Free Survival (PFS) of patients over Rituximab-containing chemotherapy regimens, although the difference was modest (Villa et al. 2013). Other groups observed that patients who were Rituximab naïve prior to ASCT, seemed

to achieve better results than those with prior Rituximab exposure (Wirk et al. 2014; Kuruvilla et al. 2015; Ban-Hoefen et al. 2012; Gisselbrecht et al. 2010; Villa et al. 2013; Madsen et al. 2015) paralleling the observation in de novo DLBCL patients undergoing ASCT (Gisselbrecht et al. 2010). In addition, patients with early tFL performed significantly better in terms of OS, compared to those with late tFL (Link et al. 2013). ASCT had similarly outcomes in the large NCCN database, with an OS of 83% being superior compared to chemotherapy alone or ASCT without the incorporation of monoclonal antibodies (S. D. Smith et al. 2009; Villa et al. 2013).

Allogeneic transplantation in tFL has been less well studied, with small numbers of patients in mostly retrospective series. Some of these studies showed significantly inferior results than ASCT (Ramadan KM, Connors JM 2008), most probably due to the higher treatment related mortality (TRM) associated with the allogeneic approach (35% versus 10% at 5 years). In contrast, the risk of disease relapse at 5 years was tendentially lower.

For relapses after ASCT, further salvage therapy with allogeneic transplantation seemed to improve the outcome of tFL regardless of the significant transplant related mortality (Ratanatharathorn et al. 1994; Doocey et al. 2005).

Radioimmunotherapy (RIT) has been proposed as primary treatment for tFL. In particular, radioactive nucleotide antibodies yttrium Y^{90} ibritumomab (Zevalin) and iodine I^{131} tositumomab (Bexxar), have shown some anti-lymphoma activity in tFL patients (A. J. Davies et al. 2004; Kaminski et al. 2001; Vose et al. 2000; Witzig et al. 2002). The overall response rates of RIT was 51%, ranging from 39% and 79%, with half of the responders achieving complete remissions (CR) (Wang and Hou 2010). (Izidore S. Lossos and Gascoyne 2011). In the largest of these studies, Zelenetz et al., (Zelenetz AD, Saleh M, Vose J 2002) evaluated 71 patients from several I^{131} tositumomab studies, and showed a median duration of response of 36 months in responding patients. Although this approach seemed less effective in patients with bulky tumor burden and patients who

have previously received radiotherapy, it might be considered especially in patients not qualifying for more aggressive approaches giving that CR patients have shown prolonged response, often longer than 1 year (Izidore S. Lossos and Gascoyne 2011).

Moreover, an additional area of interest involves the integration of RIT with HDT and transplant in tFL patients, that has the potential to improve disease control, with similar toxicities compare to HDT alone (Krishnan et al. 2008; Wondergem et al. 2012; Reddy and Savani 2011; Mei et al. 2014).

Recently, novel agents have been investigated in tFL. In a phase 2 study, Lenalidomide showed an overall response rate of 57%, with median response duration of over 1 year in tFL patients (Czuczman et al. 2011). Specific inhibitors, targeting Aurora A kinase (alisertib) (Jonathan W. Friedberg et al. 2014), Bruton tyrosine kinase (ibrutinib) (Aalipour and Advani 2013), the θ isoform of phosphatidylinositol 3-kinase (idelalisib) (Gopal et al. 2014; Burger and Okkenhaug 2014) and the BCL2 protein (GDC-0199/ABT199) (Seymour JF et al. 2013), are currently being investigated in both indolent and aggressive lymphomas. These novel agents seem to have a significant impact on the outcome of tFL patients.

Recent efforts are focusing on the immune tolerance towards lymphoma cells as an alternative therapeutic approach. Pidilizumab is currently used as a monoclonal antibody to Programmed death-1 (PD-1), a member of the B7 receptor family that represents an important immune checkpoint regulator. Its efficacy has been recently shown in ASCT patients with DLBCL, including a subset with tFL (Armand et al. 2013).

Conclusions

HT is expected as a relatively frequent event in the clinical course of patients with indolent lymphoma. However, The incidence of HT varies enormously amongst different series, pending on the definition of HT, which is different in different studies., and different treatment approaches of the FL. Based on the available published studies, mostly derived from small retro-

spective studies, there is still not any standard therapeutic strategy for tFL patients: treatments used are different in different reports and relationship between treatment and outcome does not emerge very well from the literature. The fact that the risk of transformation is rarely an end-point in prospective studies underlined a great obstacle in this field, so there is no clear evidence that the initial management has an impact on the subsequent risk of transformation.

In conclusion, There is need for further studies aiming to provide an answer to pending question, including i. Definition of tFL; ii. Assesment of risk of transformation in non-treated patients; iii. Potential role of a FL stem cell or repopulating cell as a potential cell of origin contributing to histologic transformation; iv. History of clonal evolution; v. Molecular determinants; vi. Response to salvage therapy of tFL; vii. Outcome of tFL in the Rituximab era.

In addition, other several questions should be addressed, such as whether De novo tFL is the same or a different disease; whether FL3b is different from tFL and if there are differences between tFL at first or subsequent relapse.

References

- Aalipour, Amin, and Ranjana H. Advani (2013), Bruton Tyrosine Kinase Inhibitors: A Promising Novel Targeted Treatment for B Cell Lymphomas. *British Journal of Haematology*. doi:10.1111/bjh.12573.
- Al-Tourah, Abdulwahab J, Karamjit K Gill, Mukesh Chhanabhai, Paul J Hoskins, Richard J Klasa, Kerry J Savage, Laurie H Sehn, Tamara N Shenkier, Randy D Gascoyne, and Joseph M Connors (2008), Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology* 26 (32): 5165–69. doi:10.1200/JCO.2008.16.0283.
- Andreadis, C, S J Schuster, E A Chong, J Svoboda, S M Luger, D L Porter, D E Tsai, et al. (2005), Long-Term Event-Free Survivors after High-Dose Therapy and Autologous Stem-Cell Transplantation for Low-Grade Follicular Lymphoma. *Bone Marrow Transplantation* 36 (11): 955–61. doi:10.1038/sj.bmt.1705178.
- Ardeshtna, Kirit M, Wendi Qian, Paul Smith, Nivette Braganca, Lisa Lowry, Pip Patrick, June Warden, et al. (2014), Rituximab versus a Watch-and-Wait Approach in Patients with Advanced-Stage, Asymptomatic, Non-Bulky Follicular Lymphoma: An Open-Label Randomised Phase 3 Trial. *The Lancet. Oncology* 15 (4): 424–35. doi:10.1016/S1470-2045(14)70027-0.
- Armand, Philippe, Arnon Nagler, Edie A. Weller, Steven M. Devine, David E. Avigan, Yi Bin Chen, Mark S. Kaminski, et al. (2013), Disabling Immune Tolerance by Programmed Death-1 Blockade with Pidilizumab after Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. *Journal of Clinical Oncology* 31 (33): 4199–4206. doi:10.1200/JCO.2012.48.3685.
- Bains, P, A Al Tourah, B A Campbell, T Pickles, R D Gascoyne, J M Connors, and K J Savage. (2013), Incidence of Transformation to Aggressive Lymphoma in Limited-Stage Follicular Lymphoma Treated with Radiotherapy. *Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO* 24 (2): 428–32. doi:10.1093/annonc/mds433.
- Ban-Hoefen, Makiko, Jennifer L. Kelly, Steven H. Bernstein, Jane Liesveld, Louis Constine, Michael Becker, Laurie Milner, Gordon Phillips, and Jonathan W. Friedberg. (2012), High-Dose Therapy and Autologous Stem Cell Transplant for Transformed Non-Hodgkin Lymphoma in the Rituximab Era. *Leukemia & Lymphoma*. doi:10.3109/10428194.2011.631637.
- Ban-Hoefen, Makiko, Ann Vanderplas, Allison L Crosby-Thompson, Gregory A Abel, Myron S Czuczman, Leo I Gordon, Mark S Kaminski, et al. (2013), Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the NCCN Outcomes Database. *British Journal of Haematology* 163 (4): 487–95. doi:10.1111/bjh.12570.
- Bastion, Y, C Sebban, F Berger, P Felman, G Salles, C Dumontet, P A Bryon, and B Coiffier. (1997), Incidence, Predictive Factors, and Outcome of Lymphoma Transformation in Follicular Lymphoma Patients. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology* 15 (4): 1587–94.
- Berglund, A, G Enblad, K Carlson, B Glimelius, and H Hagberg. (2000), Long-Term Follow-up of Autologous Stem-Cell Transplantation for Follicular and Transformed Follicular Lymphoma. *European Journal of Haematology* 65 (1): 17–22. doi:10.1034/j.1600-0609.2000.90114.x.
- Bouska, Alyssa, Timothy W. McKeithan, Karen E. Deffenbacher, Cynthia Lachel, George W. Wright, Javed Iqbal, Lynette M. Smith, et al. (2014), Genome-Wide Copy-Number Analyses Reveal Genomic Abnormalities Involved in Transformation of Follicular Lymphoma. *Blood* 123 (11): 1681–90. doi:10.1182/blood-2013-05-500595.
- Burger, Jan a, and Klaus Okkenhaug. (2014), Haematological Cancer: Idelalisib-Targeting PI3Kδ in Patients with B-Cell Malignancies. *Nature Reviews. Clinical Oncology* 11 (4): 184–86. doi:10.1038/nrclinonc.2014.42.
- Carlotti, Emanuela, David Wrench, Janet Matthews, Sameena Iqbal, Andrew Davies, Andrew Norton, Jason Hart, et al. (2009), Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma May Occur by Divergent Evolution from a Common Progenitor Cell or by Direct Evolution from the Follicular Lymphoma Clone. *Blood* 113 (15): 3553–57. doi:10.1182/blood-2008-08-174839.
- Casulo, Carla, W Richard Burack, and Jonathan W Friedberg. (2015), Transformed Follicular Non-Hodgkin Lymphoma. *Blood* 125 (1): 40–47. doi:10.1182/blood-2014-04-516815.
- Chen, Christine I, Michael Crump, Richard Tsang, A. Keith Stewart, and Armand Keating. (2001). Autotransplants for Histologically Transformed Follicular Non-Hodgkin's Lymphoma. *British Journal of Haematology* 113 (1): 202–8. doi:10.1046/j.1365-2141.2001.02705.x.
- Conconi, Annarita, Carlotta Ponzio, Chiara Lobetti-Bodoni, Maddalena Motta, Paola M V Rancoita, Anastasios Stathis, Alden A Moccia, et al. (2012), Incidence, Risk Factors and Outcome of Histological Transformation in Follicular Lymphoma. *British Journal of Haematology* 157 (2): 188–96. doi:10.1111/j.1365-2141.2012.09054.x.
- Czuczman, Myron S., Julie M. Vose, Thomas E. Witzig, Pier L. Zinzani, Rena Buckstein, Jonathan Polikoff, Ju Li, Dennis Pietronigro, Annetti Ervin-Haynes, and Craig B. Reeder. (2011), The Differential Effect of Lenalidomide Monotherapy in Patients with Relapsed or Refractory Transformed Non-Hodgkin

- Lymphoma of Distinct Histological Origin. *British Journal of Haematology* 154 (4): 477–81. doi:10.1111/j.1365-2141.2011.08781.x.
- Davies, A. J., A. Z S Rohatiner, S. Howell, K. E. Britton, S. E. Owens, I. N. Micallef, D. P. Deakin, et al. (2004), Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology* 22 (8): 1469–79. doi:10.1200/JCO.2004.06.055.
 - Davies, Andrew J., Andreas Rosenwald, George Wright, Abigail Lee, Kim W. Last, Dennis D. Weisenburger, Wing C. Chan, et al. (2007), Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Proceeds by Distinct Oncogenic Mechanisms. *British Journal of Haematology* 136 (2): 286–93. doi:10.1111/j.1365-2141.2006.06439.x.
 - de Jong, Daphne. (2005), Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors. *Journal of Clinical Oncology*. doi:10.1200/JCO.2005.26.856.
 - de Jong, Daphne, and Jan Paul de Boer. (2009), Predicting Transformation in Follicular Lymphoma. *Leukemia & Lymphoma* 50 (9): 1406–11. doi:10.1080/10428190903093815.
 - Doocey, Richard T., Cynthia L. Toze, Joseph M. Connors, Thomas J. Nevill, Randy D. Gascoyne, Michael J. Barnett, Donna L. Forrest, et al. (2005), Allogeneic Haematopoietic Stem-Cell Transplantation for Relapsed and Refractory Aggressive Histology Non-Hodgkin Lymphoma. *British Journal of Haematology* 131 (2): 223–30. doi:10.1111/j.1365-2141.2005.05755.x.
 - Eide, Marianne Brodtkorb, Knut Liestøl, Ole Christian Lingjaerde, Marit E Hystad, Stine H Kresse, Leonardo Meza-Zepeda, Ola Myklebost, et al. (2010), Genomic Alterations Reveal Potential for Higher Grade Transformation in Follicular Lymphoma and Confirm Parallel Evolution of Tumor Cell Clones. *Blood* 116 (9): 1489–97. doi:10.1182/blood-2010-03-272278.
 - Foran, J. M., J. Apostolidis, D. Papamichael, A. J. Norton, J. Matthews, J. A L Amess, T. A. Lister, and A. Z S Rohatiner. (1998), High-Dose Therapy with Autologous Haematopoietic Support in Patients with Transformed Follicular Lymphoma: A Study of 27 Patients from a Single Centre. *Annals of Oncology* 9 (8): 865–69. doi:10.1023/A:1008349427337.
 - Freedman, A S, J Ritz, D Neuberger, K C Anderson, S N Rabinowe, P Mauch, T Takvorian, R Soiffer, K Blake, and B Yeap. (1991), Autologous Bone Marrow Transplantation in 69 Patients with a History of Low-Grade B-Cell Non-Hodgkin's Lymphoma. *Blood* 77 (11): 2524–29.
 - Friedberg, J W, D Neuberger, J G Gribben, P Mauch, K C Anderson, R J Soiffer, T Takvorian, et al. (1999), Autologous Bone Marrow Transplantation after Histologic Transformation of Indolent B Cell Malignancies. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation* 5 (4): 262–68. doi:10.1053/bbmt.1999.v5.pm10465106.
 - Friedberg, Jonathan W., Daruka Mahadevan, Erin Cebula, Daniel Persky, Izidore Lossos, Amit B. Agarwal, JungAh Jung, et al. (2014), Phase Ii Study of Alisertib, a Selective Aurora a Kinase Inhibitor, in Relapsed and Refractory Aggressive B- And T-Cell Non-Hodgkin Lymphomas. *Journal of Clinical Oncology* 32 (1): 44–50. doi:10.1200/JCO.2012.46.8793.
 - Friedberg, Jonathan W, Michael D Taylor, James R Cerhan, Christopher R Flowers, Hildy Dillon, Charles M Farber, Eric S Rogers, et al. (2009), Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 27 (8): 1202–8. doi:10.1200/JCO.2008.18.1495.
 - Gisselbrecht, Christian, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C. Linch, Marek Trneny, Andre Bosly, et al. (2010), Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. *Journal of Clinical Oncology* 28 (27): 4184–90. doi:10.1200/JCO.2010.28.1618.
 - Gisselbrecht, Christian, Norbert Schmitz, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, et al. (2012), Rituximab Maintenance Therapy after Autologous Stem-Cell Transplantation in Patients with Relapsed CD20(+) Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 30 (36): 4462–69. doi:10.1200/JCO.2012.41.9416.
 - Gopal, Ajay K, Brad S Kahl, Sven de Vos, Nina D Wagner-Johnston, Stephen J Schuster, Wojciech J Jurczak, Ian W Flinn, et al. (2014), PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. *N Engl J Med* 370 (11): 1008–18. doi:10.1056/NEJMoa1314583.
 - Green, Michael R., Andrew J. Gentles, Ramesh V. Nair, Jonathan M. Irish, Shingo Kihira, Chih Long Liu, Itai Kela, et al. (2013), Hierarchy in Somatic Mutations Arising during Genomic Evolution and Progression of Follicular Lymphoma. *Blood* 121 (9): 1604–11. doi:10.1182/blood-2012-09-457283.
 - Guirguis, Hany R, Matthew C Cheung, Eugenia Piliotis, David Spaner, Neil L Berinstein, Kevin Imrie, Liying Zhang, and Rena Buckstein. (2014), Survival of Patients with Transformed Lymphoma in the Rituximab Era. *Annals of Hematology* 93 (6): 1007–14. doi:10.1007/s00277-013-1991-y.
 - Habermann, Thomas M, Edie A Weller, Vicki A Morrison, Randy D Gascoyne, Peter A Cassileth, Jeffrey B Cohn, Shaker R Dakhil, et al. (2006), Rituxi-

- mab-CHOP versus CHOP Alone or with Maintenance Rituximab in Older Patients with Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 24 (19): 3121–27. doi:10.1200/JCO.2005.05.1003.
- Haioun, C, N Mounier, J F Emile, D Ranta, B Coiffier, H Tilly, C Récher, et al. (2009), Rituximab versus Observation after High-Dose Consolidative First-Line Chemotherapy with Autologous Stem-Cell Transplantation in Patients with Poor-Risk Diffuse Large B-Cell Lymphoma. *Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO* 20 (12): 1985–92. doi:10.1093/annonc/mdp237.
 - Halldórsdóttir, Anna Margrét, Margareta Frühwirth, Alexander Deutsch, Ariane Aigelsreiter, Christine Beham-Schmid, Bjarni A. Agnarsson, Peter Neumeister, and W. Richard Burack. (2008), Quantifying the Role of Aberrant Somatic Hypermutation in Transformation of Follicular Lymphoma. *Leukemia Research* 32 (7): 1015–21. doi:10.1016/j.leukres.2007.11.028.
 - Hamadani, Mehdi, Don M. Benson, Thomas S. Lin, Pierluigi Porcu, Kristie A. Blum, and Steven M. Devine. (2008), High-Dose Therapy and Autologous Stem Cell Transplantation for Follicular Lymphoma Undergoing Transformation to Diffuse Large B-Cell Lymphoma. *European Journal of Haematology* 81 (6): 425–31. doi:10.1111/j.1600-0609.2008.01146.x.
 - Kaminski, M. S., A. D. Zelenetz, O. W. Press, M. Saleh, J. Leonard, L. Fehrenbacher, T. A. Lister, et al. (2001), Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. *Journal of Clinical Oncology* 19 (19): 3918–28.
 - Krishnan, Amrita, Auayporn Nademane, Henry C. Fung, Andrew A. Raubitschek, Arturo Molina, Dave Yamauchi, Roberto Rodriguez, et al. (2008), Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients with Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology* 26 (1): 90–95. doi:10.1200/JCO.2007.11.9248.
 - Küppers, Ralf. (2005), Mechanisms of B-Cell Lymphoma Pathogenesis. *Nature Reviews. Cancer* 5 (4): 251–62. doi:10.1038/nrc1589.
 - Kuruvilla, John, David A MacDonald, C Tom Kouroukis, Matthew Cheung, Harold J Olney, A Robert Turner, Peter Anglin, et al. (2015), Salvage Chemotherapy and Autologous Stem Cell Transplantation for Transformed Indolent Lymphoma: A Subset Analysis of NCIC CTG LY12. *Blood* 126 (6): 733–38. doi:10.1182/blood-2015-01-622084.
 - Lerch, K, A H Meyer, A Stroux, C Hirt, U Keller, A Viardot, R Marks, S Schreiber, A Pezzutto, and C W Scholz. (2015), Impact of Prior Treatment on Outcome of Transformed Follicular Lymphoma and Relapsed de Novo Diffuse Large B Cell Lymphoma: A Retrospective Multicentre Analysis. *Annals of Hematology* 94 (6): 981–88. doi:10.1007/s00277-015-2303-5.
 - Link, Brian K, Matthew J Maurer, Grzegorz S Nowakowski, Stephen M Ansell, William R Macon, Sergei I Syrbu, Susan L Slager, et al. (2013), Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 31 (26): 3272–78. doi:10.1200/JCO.2012.48.3990.
 - Lossos, I S. (2005), Higher-Grade Transformation of Follicular Lymphoma -- a Continuous Enigma. *Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K* 19 (8): 1331–33. doi:10.1038/sj.leu.2403801.
 - Lossos, Izidore S., and Randy D. Gascoyne. (2011), Transformation of Follicular Lymphoma. *Best Practice and Research: Clinical Haematology* 24 (2): 147–63. doi:10.1016/j.beha.2011.02.006.
 - Madsen, C, M B Pedersen, M Ø Vase, K Bendix, M B Møller, P Johansen, B A Jensen, et al. (2015), Outcome Determinants for Transformed Indolent Lymphomas Treated with or without Autologous Stem-Cell Transplantation. *Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO* 26 (2): 393–99. doi:10.1093/annonc/mdu537.
 - Mei, Matthew, Marielle J Wondergem, Joycelynne M Palmer, Avichai Shimoni, Justin Hasenkamp, Ni-Chun Tsai, Jennifer Simpson, et al. (2014), Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation* 20 (12): 2072–75. doi:10.1016/j.bbmt.2014.07.028.
 - Montoto, Silvia. (2015), Treatment of Patients with Transformed Lymphoma. *Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program* 2015: 625–30. doi:10.1182/asheducation-2015.1.625.
 - Montoto, Silvia, Andrew John Davies, Janet Matthews, Maria Calaminici, Andrew J Norton, John Amess, Sarah Vinnicombe, Rachel Waters, Ama Z S Rohatiner, and T Andrew Lister. (2007), Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 25 (17): 2426–33. doi:10.1200/JCO.2006.09.3260.
 - Montoto, Silvia, and Jude Fitzgibbon. (2011), Transformation of Indolent B-Cell Lymphomas. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 29 (14): 1827–34. doi:10.1200/JCO.2010.32.7577.

- Morin, Ryan D, Nathalie A Johnson, Tesa M Severson, Andrew J Mungall, Jianghong An, Rodrigo Goya, Jessica E Paul, et al. (2010), Somatic Mutations Altering EZH2 (Tyr641) in Follicular and Diffuse Large B-Cell Lymphomas of Germinal-Center Origin. *Nature Genetics* 42 (2): 181–85. doi:10.1038/ng.518.
- Morin, Ryan D, Maria Mendez-Lago, Andrew J Mungall, Rodrigo Goya, Karen L Mungall, Richard D Corbett, Nathalie A Johnson, et al. (2011), Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma. *Nature* 476 (7360): 298–303. doi:10.1038/nature10351.
- Okosun, Jessica, Csaba Bödör, Jun Wang, Shamzah Araf, Cheng-Yuan Yang, Chenyi Pan, Sören Boller, et al. (2014), Integrated Genomic Analysis Identifies Recurrent Mutations and Evolution Patterns Driving the Initiation and Progression of Follicular Lymphoma. *Nature Genetics* 46 (2): 176–81. doi:10.1038/ng.2856.
- Pasqualucci, Laura, Hossein Khiabani, Marco Fanfani, Mansi Vasishtha, Monica Messina, Antony B Holmes, Peter Ouillette, et al. (2014), Genetics of Follicular Lymphoma Transformation. *Cell Reports* 6 (1): 130–40. doi:10.1016/j.celrep.2013.12.027.
- Ramadan KM, Connors JM, Al-Tourah AL et al. (2008), Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/relapsed Transformed Lymphoma. *Blood* 112: 4459.
- Ratanatharathorn, V, J Uberti, C Karanes, E Abella, L G Lum, F Momin, G Cummings, and L L Sensenbrenner. (1994), Prospective Comparative Trial of Autologous versus Allogeneic Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma. *Blood*. Vol. 84.
- Reddy, Nishitha, and Bipin N. Savani. (2011), Treatment Options for Transformed Lymphoma: Incorporating Allogeneic Stem Cell Transplantation in a Multimodality Approach. *Biology of Blood and Marrow Transplantation*. doi:10.1016/j.bbmt.2011.05.002.
- Ruminy, Philippe, Fabrice Jardin, Jean-Michel Picquenot, Françoise Parmentier, Nathalie Contentin, Gérard Buchonnet, Sandrine Tison, Vinciane Rainville, Hervé Tilly, and Christian Bastard. (2008), S(mu) Mutation Patterns Suggest Different Progression Pathways in Follicular Lymphoma: Early Direct or Late from FL Progenitor Cells. *Blood* 112 (5): 1951–59. doi:10.1182/blood-2007-11-124560.
- Sabloff, Mitchell, Harold L. Atkins, Isabelle Bence-Bruckler, Christopher Bredeson, Dean Fergusson, Paul Genest, Harry Hopkins, Brian Hutton, Sheryl McDiarmid, and Lothar B. Huebsch. (2007), A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular Lymphoma. *Biology of Blood and Marrow Transplantation* 13 (8): 956–64. doi:10.1016/j.bbmt.2007.04.009.
- Sarkozy, Clémentine, Marek Trneny, Luc Xerri, Nick Wickham, Pierre Feugier, Sirpa Leppä, Pauline Brice, et al. (2016), Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, June. doi:10.1200/JCO.2015.65.7163.
- Schouten, H C, P J Bierman, W P Vaughan, A Kessinger, J M Vose, D D Weisenburger, and J O Armitage. (1989), Autologous Bone Marrow Transplantation in Follicular Non-Hodgkin's Lymphoma before and after Histologic Transformation. *Blood* 74 (7): 2579–84.
- Seymour JF et al. (2013), Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumour Activity Including Complete Remissions in High-Risk Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) [Abstract]. *Blood* 122 ((21)): 872.
- Sherr, Charles J. (2004), Principles of Tumor Suppression. *Cell*. doi:10.1016/S0092-8674(03)01075-4.
- Smith, Sonali M. (2013), Dissecting Follicular Lymphoma: High versus Low Risk. Hematology / the Education Program of the American Society of Hematology. *American Society of Hematology*. Education Program 2013: 561–67. doi:10.1182/asheducation-2013.1.561.
- Smith, Stephen D, Brian J Bolwell, Anjali S Advani, Steven W Andresen, Josephine L Chan, Robert M Dean, Eric D Hsi, et al. (2009), High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant: Pathologic Analysis and Comparison with de Novo Diffuse Large B-Cell Lymphoma. *Leukemia & Lymphoma* 50 (10): 1625–31. doi:10.1080/10428190903128652.
- Solal-Céligny, Philippe, Monica Bellei, Luigi Marcheselli, Emanuela Anna Pesce, Stefano Pileri, Peter McLaughlin, Stefano Luminari, et al. (2012), Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology* 30 (31): 3848–53. doi:10.1200/JCO.2010.33.4474.
- Swerdlow SH, Campo E, Harris NL. (2008), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed. Lyon. IARC Press.
- Villa, Diego, Michael Crump, Tony Panzarella, Kerry J. Savage, Cynthia L. Toze, Douglas A. Stewart, David A. MacDonald, et al. (2013), Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. *Journal of Clinical Oncology* 31 (9): 1164–71. doi:10.1200/JCO.2012.44.0693.
- Vose, J M, R L Wahl, M Saleh, A Z Rohatiner, S J Knox, J A Radford, A D Zelenetz, G F Tidmarsh, R J

- Stagg, and M S Kaminski. (2000), Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. Vol. 18.
- Wagner-Johnston, Nina D, Brian K Link, Michelle Byrtek, Keith L Dawson, John Hainsworth, Christopher R Flowers, Jonathan W Friedberg, and Nancy L Bartlett. (2015), Outcomes of Transformed Follicular Lymphoma in the Modern Era: A Report from the National LymphoCare Study (NLCS). *Blood* 126 (7): 851–57. doi:10.1182/blood-2015-01-621375.
 - Wang, Hua Qing, and Yun Hou. (2010), The Incidence, Natural History, Biology, and Treatment of Transformed Lymphomas. *Journal of Leukemia and Lymphoma* 19 (4): 193–95. doi:10.3760/cma.j.issn.1009-9921.2010.04.001.
 - Wartenberg, Martin, Peter Vasil, Christian Meyer zum Bueschenfelde, German Ott, Andreas Rosenwald, Falko Fend, and Marcus Kremer. (2013), Somatic Hypermutation Analysis in Follicular Lymphoma Provides Evidence Suggesting Bidirectional Cell Migration between Lymph Node and Bone Marrow during Disease Progression and Relapse. *Haematologica* 98 (9): 1433–41. doi:10.3324/haematol.2012.074252.
 - Williams, C. D., C. N. Harrison, T. A. Lister, A. J. Norton, A. K. Blystad, B. Coiffier, G. Taghipour, N. Schmitz, and A. H. Goldstone. (2001), High-Dose Therapy and Autologous Stem-Cell Support for Chemosensitive Transformed Low-Grade Follicular Non-Hodgkin's Lymphoma: A Case-Matched Study from the European Bone Marrow Transplant Registry. *Journal of Clinical Oncology* 19 (3): 727–35.
 - Wirk, Baldeep, Timothy S Fenske, Mehdi Hamadani, Mei-Jie Zhang, Zhen-Huan Hu, Görgün Akpek, Mahmoud D Aljurf, et al. (2014), Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation* 20 (7): 951–59. doi:10.1016/j.bbmt.2014.03.014.
 - Witzig, Thomas E., Leo I. Gordon, Fernando Cabanillas, Myron S. Czuczman, Christos Emmanouilides, Robin Joyce, Brad L. Pohlman, et al. (2002), Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy versus Rituximab Immunotherapy for Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology* 20 (10): 2453–63. doi:10.1200/JCO.2002.11.076.
 - Wondergem, Marielle J, Josee M Zijlstra, Madelon de Rooij, Otto J Visser, Peter C Huijgens, and Sonja Zweegman. (2012), Improving Survival in Patients with Transformed B Cell Non Hodgkin Lymphoma: Consolidation with 90Yttrium Ibritumomab Tiuxetan-BEAM and Autologous Stem Cell Transplantation. *British Journal of Haematology* 157 (3): 395–97. doi:10.1111/j.1365-2141.2011.08991.x.
 - Yuen, A. R., O. W. Kamel, J. Halpern, and S. J. Horning. (1995), Long-Term Survival after Histologic Transformation of Low-Grade Follicular Lymphoma. *Journal of Clinical Oncology* 13 (7): 1726–33.
 - Zelenetz AD, Saleh M, Vose J, et al. (2002), Patients with Transformed Low Grade Lymphoma Attain Durable Responses Following Outpatient Radioimmunotherapy with Tositumomab and Iodine I 131 Tositumomab (Bexxar) (Abstract 1384). *Blood*: 100: 357a.